Actinium Pharmaceuticals
ATNM
30 hedge funds and large institutions have $8.43M invested in Actinium Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
49% more capital invested
Capital invested by funds: $5.66M → $8.43M (+$2.77M)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
11% more funds holding
Funds holding: 27 → 30 (+3)
0.21% more ownership
Funds ownership: 0.23% → 0.44% (+0.21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$2.74M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.37M |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$183K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$155K |
| 5 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$63.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$247K |
| 2 |
Bank of New York Mellon
New York
|
-$77.4K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
-$43K |
| 4 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$23.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CLOS
26
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| $7K | -$23.9K | -466 | -74% |
|
|
AG
27
Advisor Group
Phoenix,
Arizona
| $3K | – | – | – |
|
28
Bank of Montreal
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
29
US Bancorp
Minneapolis,
Minnesota
| $1K | +$1.08K | +21 | New |
|
|
GCP
30
GSA Capital Partners
London,
United Kingdom
| – | -$247K | -4,647 | Closed |
|
|
31
Nomura Holdings
Tokyo,
Japan
| – | -$43K | -798 | Closed |
|
|
32
UBS Group
Zurich,
Switzerland
| – | -$9K | -172 | Closed |
|
|
CG
33
Cutler Group
San Francisco,
California
| – | +$872 | +17 | New |
|
ATNM Hedge Fund Activity: Q3 2016 in Review
30 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2016, worth a combined $8.43M — up 49% from $5.66M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ATNM positions and 4 closed out — a net gain of 3 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $2.74M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $247K sold.
- 30 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2016, up from 27 in Q2 2016.
- Funds reported $8.43M of Actinium Pharmaceuticals stock for Q3 2016, up 49% quarter-over-quarter.
- 7 funds opened new Actinium Pharmaceuticals positions in Q3 2016 and 4 closed out, a net change of +3 holders.
- The largest Actinium Pharmaceuticals buyer in Q3 2016 was Sio Capital Management, an estimated $2.74M added.
- The largest Actinium Pharmaceuticals seller in Q3 2016 was GSA Capital Partners, an estimated $247K sold.
Based on aggregated 13F filings for Q3 2016.